Clinical Trials in San Francisco

Showing 5321-5340 of 9,883 trials

124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patients With Neuroblastoma: A Pilot Study

NCT01583842

This is a pilot study with the primary purpose to describe organ dosimetry and acute toxicities using no carrier added and carrier added 124I-MIBG PET/CT in patients with neuroblastoma (NB). Eligible patients are 3 years of age and older with relapsed or refractory neuroblastoma who are currently enrolled on a treatment protocol with 131I-MIBG. After all eligibility criteria are met, patients will receive a diagnostic imaging dose of 124I-MIBG followed by sequential PET/CT dosimetry scans on Days 0, 1, 2 and 5. Subsequent, planned therapeutic administration of 131I-MIBG will occur between Days 7 to 21, as specified by the patient's therapeutic MIBG protocol. An optional single follow up 124I-MIBG PET-CT scan will be done to assess tumor sites 6 weeks after the patient has their MIBG therapy.

Neuroblastoma

Miguel Pampaloni10 participantsStarted Apr 2013

San Francisco, California, United States

COMPLETEDPhase 1/2< 1 mile

A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer

NCT00452413

Phase I: A study to see what doses of Enzastaurin and Erlotinib are best tolerated by participants with solid tumor cancer. Phase II: A study to see how long participants with non-small cell lung cancer (NSCLC) treated with Enzastaurin and Erlotinib live.

Non-Small Cell Lung CancerMalignant Solid Tumor

Eli Lilly and Company65 participantsStarted May 2007

Los Angeles, California, United States • Palo Alto, California, United States • San Francisco, California, United States +7 more locations

124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patients With Neuroblastoma: A Pilot Study

A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer

Find Trials by Condition in San Francisco

GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma

An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension

Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer

Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy

Lead Registry for Optim Leads

A Long Term Study of the Safety of Tanezumab When Administered By Subcutaneous Injections

Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)

Health Literacy in Adults With Congenital Heart Disease

Environmental Strategies & Behavior Change to Reduce Overeating in Obese Children

The AMOR Method: Resilience Training for Parents of Children With Autism

Suprachoroidal CLS-TA With Intravitreal Aflibercept Versus Aflibercept Alone in Subject With Diabetic Macular Edema

Extension Study Of Tanezumab In Osteoarthritis

St. Jude Medical Product Longevity and Performance (SCORE) Registry

Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis

Tanezumab In Osteoarthritis Of The Hip Or Knee

Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin

Maribavir for Prevention of CMV After Stem Cell Transplants

Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects